Annual report
4188.TEDINET S100W27P
Period2024-04-01 → 2025-03-31
Filed2025-06-23
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Amended by S100WZVZ (2025-11-12).
Key figures · 160
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.41T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥4.39T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥4.63T | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.98T | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.26T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥196.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥261.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥150.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥240.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥168.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥290.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥32.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥45.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥119.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥96.5bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥177.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥7.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥105.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥178.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥135.5bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥209.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥22.7bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥5.89T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥6.10T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥5.77T | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.57T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.29T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥3.61T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥3.83T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.28T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.28T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.99T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.74T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.76T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.56T | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.46T | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.24T | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥326.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥294.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥297.2bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥245.8bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥349.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥552.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥465.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥355.2bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥346.9bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥467.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥275.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥246.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥247.6bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥128.8bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥217.0bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥246.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥241.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.8bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥336.3bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥142.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥31.64 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥84.07 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥67.85 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥124.68 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-5.32 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥31.63 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥80.77 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥64.99 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥115.03 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-5.32 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,223.01 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,239.61 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,100.27 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,026.03 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥870.4 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 29.5% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.9% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.1% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.2% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 23.4% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 2.6% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -0.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 63,258 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 66,358 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 68,639 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 69,784 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 69,607 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥75.8bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥212.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥125.3bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥69.5bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥24.7bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥55.6bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥190.4bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥51.6bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥186.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥103.1bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥52.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.4bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥51.6bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥189.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥137.7bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥188.8bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥104.5bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥56.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥11.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.97T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥1.99T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.01T | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.80T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.99T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.27T | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.38T | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥706.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥614.5bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥471.4bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥409.7bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥392.3bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥22.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥26.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥96.73 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥132.74 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.51 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.56 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.37 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥96.71 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥127.46 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥70.41 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.62 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.87 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥32 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥496.53 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥431.67 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.8 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥286.54 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥273.62 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 35.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.3% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 20.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 34.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 23.9% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,506,288,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,506,288,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,506,288,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,506,288,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,506,288,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 414 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 501 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 430 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 223 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 201 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥2.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 6257 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥335.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥190.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥145.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥253.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥13.4bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥211.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥211.8bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥358.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥11.4bn |
| Basic Materials And Polymersreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥46.8bn |
| Basic Materials And Polymersreportable segment | employees | at 2025-03-31 | 6572 pure |
| Basic Materials And Polymersreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.01T |
| Basic Materials And Polymersreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥972.4bn |
| Basic Materials And Polymersreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥34.8bn |
| Basic Materials And Polymersreportable segment | segment assets | at 2025-03-31 | ¥704.4bn |
| Basic Materials And Polymersreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥15.6bn |
| Industrial Gasesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥142.4bn |
| Industrial Gasesreportable segment | employees | at 2025-03-31 | 19762 pure |
| Industrial Gasesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.31T |
| Industrial Gasesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.30T |
| Industrial Gasesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.9bn |
| Industrial Gasesreportable segment | segment assets | at 2025-03-31 | ¥2.46T |
| Industrial Gasesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥186.1bn |
| MMA And Derivativesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥23.4bn |
| MMA And Derivativesreportable segment | employees | at 2025-03-31 | 3995 pure |
| MMA And Derivativesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥416.4bn |
| MMA And Derivativesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥402.1bn |
| MMA And Derivativesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥14.3bn |
| MMA And Derivativesreportable segment | segment assets | at 2025-03-31 | ¥529.2bn |
| MMA And Derivativesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥35.3bn |
| Pharmareportable segment | capex | 2024-04-01 → 2025-03-31 | ¥7.9bn |
| Pharmareportable segment | employees | at 2025-03-31 | 4490 pure |
| Pharmareportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥460.4bn |
| Pharmareportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥460.3bn |
| Pharmareportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥92m |
| Pharmareportable segment | segment assets | at 2025-03-31 | ¥963.0bn |
| Pharmareportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥65.4bn |
| Specialty Materialsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥114.6bn |
| Specialty Materialsreportable segment | employees | at 2025-03-31 | 21260 pure |
| Specialty Materialsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.09T |
| Specialty Materialsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.08T |
| Specialty Materialsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.3bn |
| Specialty Materialsreportable segment | segment assets | at 2025-03-31 | ¥1.34T |
| Specialty Materialsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥25.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥354.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥204.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥149.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥274.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥13.6bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥220.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥220.7bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥398.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥12.4bn |
| Basic Materials And Polymersreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥39.2bn |
| Basic Materials And Polymersreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.15T |
| Basic Materials And Polymersreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.11T |
| Basic Materials And Polymersreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥39.0bn |
| Basic Materials And Polymersreportable segment | segment assets | at 2024-03-31 | ¥858.9bn |
| Basic Materials And Polymersreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥25.4bn |
| Industrial Gasesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥126.3bn |
| Industrial Gasesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.26T |
| Industrial Gasesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.25T |
| Industrial Gasesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥8.2bn |
| Industrial Gasesreportable segment | segment assets | at 2024-03-31 | ¥2.45T |
| Industrial Gasesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥163.0bn |
| MMA And Derivativesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥25.0bn |
| MMA And Derivativesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥361.8bn |
| MMA And Derivativesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥347.9bn |
| MMA And Derivativesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥13.9bn |
| MMA And Derivativesreportable segment | segment assets | at 2024-03-31 | ¥590.2bn |
| MMA And Derivativesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.5bn |
| Pharmareportable segment | capex | 2023-04-01 → 2024-03-31 | ¥5.1bn |
| Pharmareportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥437.4bn |
| Pharmareportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥437.2bn |
| Pharmareportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥138m |
| Pharmareportable segment | segment assets | at 2024-03-31 | ¥933.6bn |
| Pharmareportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥56.3bn |
| Specialty Materialsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥80.9bn |
| Specialty Materialsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.05T |
| Specialty Materialsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.04T |
| Specialty Materialsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥9.8bn |
| Specialty Materialsreportable segment | segment assets | at 2024-03-31 | ¥1.39T |
| Specialty Materialsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥7.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,436
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss IFRS | Prior1YearDuration | 178439000000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 105636000000 | JPY |
| Profit loss attributable to owners of parent IFRS | Prior1YearDuration | 119596000000 | JPY |
| Profit loss attributable to owners of parent IFRS | CurrentYearDuration | 45020000000 | JPY |
| Profit loss attributable to non controlling interests IFRS | Prior1YearDuration | 58843000000 | JPY |
| Profit loss attributable to non controlling interests IFRS | CurrentYearDuration | 60616000000 | JPY |
| Basic earnings loss per share IFRS | Prior1YearDuration | 84.07 | |
| Basic earnings loss per share IFRS | CurrentYearDuration | 31.64 | |
| Diluted earnings loss per share IFRS | Prior1YearDuration | 80.77 | |
| Diluted earnings loss per share IFRS | CurrentYearDuration | 31.63 | |
| Profit loss IFRS | Prior1YearDuration | 178439000000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 105636000000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | 7792000000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | -7818000000 | JPY |
| Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | 7295000000 | JPY |
| Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | 6091000000 | JPY |
| Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | -26000000 | JPY |
| Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | 95000000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | 15061000000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | -1632000000 | JPY |
| Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRS | Prior1YearDuration | 166868000000 | JPY |
| Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRS | CurrentYearDuration | -27682000000 | JPY |
| Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRS | Prior1YearDuration | 1163000000 | JPY |
| Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRS | CurrentYearDuration | -1115000000 | JPY |
| Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRS | Prior1YearDuration | 2066000000 | JPY |
| Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRS | CurrentYearDuration | 2257000000 | JPY |
| Total of items that may be reclassified to profit or loss oci IFRS | Prior1YearDuration | 170097000000 | JPY |
| Total of items that may be reclassified to profit or loss oci IFRS | CurrentYearDuration | -26540000000 | JPY |
| Other comprehensive income IFRS | Prior1YearDuration | 185158000000 | JPY |
| Other comprehensive income IFRS | CurrentYearDuration | -28172000000 | JPY |
| Comprehensive income IFRS | Prior1YearDuration | 363597000000 | JPY |
| Comprehensive income IFRS | CurrentYearDuration | 77464000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS | Prior1YearDuration | 249349000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS | CurrentYearDuration | 21774000000 | JPY |
| Comprehensive income attributable to non controlling interests IFRS | Prior1YearDuration | 114248000000 | JPY |
| Comprehensive income attributable to non controlling interests IFRS | CurrentYearDuration | 55690000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 294924000000 | JPY |
| Cash and cash equivalents IFRS | CurrentYearInstant | 326144000000 | JPY |
| Trade receivables ca IFRS | Prior1YearInstant | 852353000000 | JPY |
| Trade receivables ca IFRS | CurrentYearInstant | 764814000000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 799249000000 | JPY |
| Inventories ca IFRS | CurrentYearInstant | 759423000000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 82804000000 | JPY |
| Other financial assets ca IFRS | CurrentYearInstant | 66103000000 | JPY |
| Other current assets ca IFRS | Prior1YearInstant | 131721000000 | JPY |
| Other current assets ca IFRS | CurrentYearInstant | 128973000000 | JPY |
| Current assets other than assets held for sale ca IFRS | Prior1YearInstant | 2161051000000 | JPY |
| Current assets other than assets held for sale ca IFRS | CurrentYearInstant | 2045457000000 | JPY |
| Assets held for sale IFRS | Prior1YearInstant | 30585000000 | JPY |
| Assets held for sale IFRS | CurrentYearInstant | 16103000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |